Overview

In this activity, Dr. Rini reviews a patient case with intermediate RCC and explores appropriate treatment options. Learners are walked through patient risk stratification and therapy selection supported by a review of clinical trial data. This discussion also provides insights into the role of PD-L1 in treatment selection and how to determine the cause of adverse events, immune-related or not.

This activity is intended for medical oncologists, urologist oncologists, surgeons and other healthcare professionals involved in the care or treatment of patients with RCC such as oncology nurses, nurse practitioners, and physician assistants.

Oncologists may be unfamiliar with newly approved and emerging immunotherapies for RCC. Additionally, clinicians need training on how to select appropriate immunotherapy and recognize whether it is demonstrating efficacy as the timeline to response success differs from that seen with cytotoxic therapies. Furthermore, strategies on how to manage toxicities which may accompany these new drugs, especially when guidelines have not incorporated these new therapies into their algorithms, are greatly needed. This activity will provide education highlighting issues and strategies around immunotherapy efficacy and risks, in order to help today’s oncologists provide optimal, cutting-edge, personalized care.

At the conclusion of this educational activity, the participant should be able to:
• Compare and contrast evidence from immunotherapy clinical trials to assess how newly approved and emerging immunotherapies improve treatment of RCC, including combination anti-VEGF and immunotherapeutic platforms (Knowledge, Competence)
• Discuss clinical factors when immunotherapy or combination immunotherapy should be considered as a treatment option for patients with RCC, such as patient selection, optimal drug combinations, and treatment sequence (Knowledge, Competence, Performance)
• Review clinical strategies for the early detection and management of immunotherapy and immunotherapy combination related adverse events in RCC patients and management plans to help mitigate them (Knowledge, Competence, Performance)

Supported by an educational grant from Pfizer and EMD Serono.